Ipca Laboratories has received voluntary action indicated (VAI) classification from the United States Food and Drug Administration (USFDA) for its manufacturing facility situated at SEZ Indore, Pithampur (Madhya Pradesh). USFDA inspected the company’s said manufacturing facility from June 15, 2023 to June 23, 2023. This facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.
